Callister S M, Schell R F, Case K L, Lovrich S D, Day S P
Microbiology Research Laboratory, Gundersen Medical Foundation, La Crosse, Wisconsin 54601.
J Infect Dis. 1993 Jan;167(1):158-64. doi: 10.1093/infdis/167.1.158.
An in vitro assay was used to characterize the borreliacidal activity of sera from Lyme disease patients. The mean percentage of killing was 23% with sera from patients with a single erythema migrans lesion, 42% from patients with multiple lesions, 58% from patients with Lyme arthritis of short duration, and 83% from patients with Lyme arthritis of long duration. Borreliacidal activity was abrogated when Lyme disease serum was treated with anti-human IgM or IgG1. In addition, human sera from Lyme arthritis patients containing borreliacidal antibody prevented the induction of Lyme arthritis in irradiated hamsters challenged with the Lyme spirochete. Removal of outer surface protein A antibodies from late Lyme disease sera caused reductions in the borreliacidal antibody titer. The results demonstrate an important role for borreliacidal antibody against infection with B. burgdorferi in humans and confirm that detection of borreliacidal antibody in human sera can be a specific serodiagnostic test for Lyme disease.
采用体外试验来表征莱姆病患者血清的杀疏螺旋体活性。单个游走性红斑皮损患者血清的平均杀伤百分比为23%，多个皮损患者血清为42%，病程短的莱姆关节炎患者血清为58%，病程长的莱姆关节炎患者血清为83%。用抗人IgM或IgG1处理莱姆病血清后，杀疏螺旋体活性消失。此外，含有杀疏螺旋体抗体的莱姆关节炎患者的人血清可预防经莱姆螺旋体攻击的辐照仓鼠发生莱姆关节炎。去除晚期莱姆病血清中的外表面蛋白A抗体导致杀疏螺旋体抗体效价降低。结果表明，杀疏螺旋体抗体在人类抗伯氏疏螺旋体感染中起重要作用，并证实检测人血清中的杀疏螺旋体抗体可作为莱姆病的特异性血清学诊断试验。
